RxDoctor Payments Data

John Matocha, MD

Family Medicine · Houston, TXNPI 1689754632

Payments from drug & device makers

$6,668in general payments, 2019–2025

Across 385 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$1K
  • Novo Nordisk$578
  • AstraZeneca$497
  • Amgen$493
  • Pfizer$450
  • AbbVie$427
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,62099%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,668 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,491
Medicare patients
408
Services billed
18,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$59,942
VascepaIcosapent Ethyl75$52,875
FarxigaDapagliflozin Propanediol39$35,970
MounjaroTirzepatide20$22,996
JardianceEmpagliflozin20$22,598
EliquisApixaban12$19,536
Icosapent Ethyl41$13,055
Repatha SureclickEvolocumab21$11,011
Doxepin Hcl11$8,190
EdarbiAzilsartan Medoxomil18$6,952
Lamictal OdtLamotrigine12$5,192
SynthroidLevothyroxine Sodium55$4,251
Atorvastatin Calcium540$4,230
Rosuvastatin Calcium445$4,136
Xigduo XrDapaglifloz Propaned/Metformin12$3,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$578$59,94257 claims
AstraZenecaFarxiga$497$35,97039 claims
Boehringer IngelheimJardiance$38$22,59820 claims
PfizerEliquis$450$19,53612 claims
Arbor Pharmaceuticals, Inc.Edarbi$74$6,95218 claims
AbbVieSynthroid$427$4,25155 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,766220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →